Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center

doi:10.4292/wjgpt.v16.i4.110273

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

(40)

(48)

(0)

(13)

(987)

(3)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Pharmacol Ther. Dec 5, 2025; 16(4): 110273
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110273

Full Size Figure Download Figure

Figure 1 Box plots demonstrating mean measurements of clinical and biochemical parameters over the different timepoints in our study. A: Mean harvey bradshaw index over time; B: Mean faecal calprotectin (μg/g) over time; C: Mean serum albumin (g/L) over time; D: Mean C-reactive protein (mg/L) over time. HBI: Harvey-Bradshaw Index; CRP: C-reactive protein.

Citation: Colwill M, Padley J, Qazi U, Mehta S, Donovan F, Alves AM, Pollok R, Patel K, Dawson P, Honap S, Poullis A. Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center. World J Gastrointest Pharmacol Ther 2025; 16(4): 110273
URL: https://www.wjgnet.com/2150-5349/full/v16/i4/110273.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v16.i4.110273

Colwill M, Padley J, Qazi U, Mehta S, Donovan F, Alves AM, Pollok R, Patel K, Dawson P, Honap S, Poullis A. Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center. World J Gastrointest Pharmacol Ther 2025; 16(4): 110273 [PMID: 41378066 DOI: 10.4292/wjgpt.v16.i4.110273]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.